{"DataElement":{"publicId":"7136499","version":"1","preferredName":"Non-Cellular Component Immunotherapy Administered Type","preferredDefinition":"The response to a question asking to specify the type of non-cellular immunotherapy administered to a patient.","longName":"NON_CELL_IMMUNE_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7136492","version":"1","preferredName":"Non-Cellular Component Immunotherapy Administered","preferredDefinition":"A term that refers to the non-cellular component of the innate immune system which includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid._Therapy designed to induce changes in a patient's immune status in order to treat disease._The act of having given something (e.g., a medication or test).","longName":"7136490v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7136490","version":"1","preferredName":"Non-Cellular Component Immunotherapy","preferredDefinition":"A term that refers to the non-cellular component of the innate immune system which includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid.:Therapy designed to induce changes in a patient's immune status in order to treat disease.","longName":"C125905:C15262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Cellular Component","conceptCode":"C125905","definition":"A term that refers to the non-cellular component of the innate immune system which includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCFC5CA-CD11-32A2-E053-F662850AC4FC","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCFC5CA-CD1F-32A2-E053-F662850AC4FC","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"SETRAKIN","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7136496","version":"1","preferredName":"Non-cellular Immunotherapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7136496v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other bispecific engager","valueDescription":"Other bispecific engager","ValueMeaning":{"publicId":"7136497","version":"1","preferredName":"Other bispecific engager","longName":"7136497","preferredDefinition":"Other bispecific engager","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D28E-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2A7-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2B1-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Other targeted antibody","valueDescription":"Other targeted antibody","ValueMeaning":{"publicId":"7136498","version":"1","preferredName":"Other targeted antibody","longName":"7136498","preferredDefinition":"Other targeted antibody","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D2BB-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2D4-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Inotuzumab Ozogamicin","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2DE-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D278-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"SETRAKIN","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of non cellular immunoth","type":"Preferred Question Text","description":"Type of non cellular immunotherapy:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0D5CE-8DEE-68B0-E053-F662850A0C2E","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"SETRAKIN","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}